DIRS.INFO The most relevant business & tech news

Analysts attended earnings calls in the third quarter armed with questions for healthcare and consumer companies about the potential effect on their sales from the growing popularity of these drugs, known as GLP-1 agonists. A Reuters analysis of earnings transcripts for the third quarter showed "GLP-1" or alternatives like "obesity" or "weight-loss medications" were mentioned 256 times across 29 U.S. and European healthcare and consumer companies. That's more than double the mentions for the second quarter, when those phrases came up 127 times. While some consumer companies have talked about factors such as fewer calories being consumed, "these kind of large extrapolations" seem to be a bit of a stretch, said BMO Capital analyst Evan Seigerman. For big pharma manufacturers like Pfizer (PFE.N) and Amgen (AMGN.O), analyst questions were aimed at their obesity drug candidates.

Persons: Lilly, George Frey, Jeff Jonas, it's, Eli Lilly's, John Furner, Mondelez, Eli Lilly, Evan Seigerman, LVMH, Rajesh Kumar, Jonas, Bhanvi Satija, Savyata Mishra, Arpan Varghese, David Gaffen, Shounak Organizations: Novo Nordisk, Pharmacy, REUTERS, Gabelli, Novo, Walmart, Walmart U.S, Hershey, Truist Securities, Krispy, BMO Capital, Danish, pharma, Pfizer, Devices, HSBC, Thomson Locations: Provo , Utah, U.S, United States, Novo, Bengaluru

☆ AI is fueling transformative new brain-health technology to detect and prevent cognitive decline
▼ + stars: | 2023-11-15 | by ( Hazel Davis | ) www.businessinsider.com time to read: +7 min

The global population is aging, presenting new challenges related to cognitive decline. One startup is building an AI tool to identify potential cognitive decline based on driving behavior. AdvertisementAs the global population ages, the challenges associated with cognitive decline become more prominent. However, cutting-edge technologies are emerging to address these challenges, with companies developing novel tools designed to detect, prevent, and manage cognitive decline. The convergence of AI, medical technology, and neurotech is leading the fight against cognitive decline.

Persons: —, Brian Mullins, Mullins, John Klepper, Klepper, Cathy Craig Organizations: Service, Japan, Mind Foundry, Dowa Insurance, PIPRA AG, Business, Royal Academy of Engineering Enterprise, Italian Rugby Federation, Elite Ice Hockey Locations: Zurich, postsurgery, London

☆ Medical device stocks rise in relief after Wegovy heart benefits data
▼ + stars: | 2023-11-13 | by ( ) www.reuters.com time to read: +2 min

A 0.25 mg injection pen of Novo Nordisk's weight-loss drug Wegovy is shown in this photo illustration in Oslo, Norway, September 1, 2023. To be sure, the full results presented on Saturday at a major medical meeting gave analysts even more confidence in the heart protective benefits of the hugely popular drug. That lifted shares of Penumbra (PEN.N), which makes devices used in surgeries for stroke patients, 13% in morning trading. Its shares have tumbled about 28% as of last close since Novo in August said Wegovy had also shown a clear cardiovascular benefit. "The full detailed results ... do not shift our outlook that MedTech device stocks appear broadly oversold," said Leerink analyst Mike Kratky.

Persons: Victoria Klesty, Wegovy, Baird, Jeff Johnson, Eli Lilly's, Mike Kratky, Leroy Leo, Medha Singh, Sriraj Organizations: REUTERS, Novo, Devices, Abbott Laboratories, Thomson Locations: Oslo, Norway, Victoria, MedTech, Penumbra, Novo, Friday's, Bengaluru

Eight of the 11 major S&P 500 sectors were in the red, with rate-sensitive real estate stocks (.SPLRCR) down 1.2% and leading declines. This week's economic data as well as speeches from Fed officials will provide clues on the trajectory of interest rates amid growing expectations that the Fed is done hiking borrowing costs. The major U.S. stock indexes have rebounded strongly this month, fueled by a stronger-than-expected earnings season and on hopes that U.S. interest rates are near their peak. The benchmark S&P 500 (.SPX) closed at near eight-week highs on Friday, while the tech-heavy Nasdaq (.IXIC) hit a two-month peak. The S&P index recorded 11 new 52-week highs and one new low, while the Nasdaq recorded 19 new highs and 82 new lows.

Persons: Brendan McDermid, Peter Cardillo, Cardillo, Mike Johnson, Abbott, advancers, Sruthi Shankar, Amruta, Maju Samuel Organizations: New York Stock Exchange, REUTERS, Boeing, Dow, Nasdaq, Federal Reserve, Treasury, Microsoft, Apple, Spartan Capital Securities, . House, Republican, Dow Jones, Novo Nordisk's, Bloomberg News, Max, NYSE, Thomson Locations: New York City, U.S, China, Bengaluru

☆ What we'd like to see from 3 economic readings and 2 earnings reports next week
▼ + stars: | 2023-11-11 | by ( Zev Fima | ) www.cnbc.com time to read: +9 min

The major averages advanced again this week as earnings results came in largely better than expected, interest rates stabilized and oil prices dropped below $80 a barrel. Looking ahead, we'll get a couple more earnings results and some key inflationary data to chew on. In this past week, we bought 150 shares of DuPont (DD) and added 75 shares of Wynn Resorts (WYNN). As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio.

Persons: Stocks, Wynn Resort's, WYNN, we'll, That's, —, we're, it's, PANW, Tyson, Henry Schein, Spero, Sanara, Sara Lee Corp, JD.com, Woodward, Jim Cramer's, Jim Cramer, Jim, Mario Anzuoni Organizations: Nasdaq, Dow Jones, Coterra Energy, Emerson, Disney, PPI, TJX, Palo Alto Networks, DuPont, Wynn Resorts, WYNN, Tyson Foods, TSN, Tower Semiconductor, Partners, Genius Sports, Spero Therapeutics, Star Bulk Carriers Corp, Beauty Health, Asure, Gladstone Capital Corp, TeraWulf Inc, Harrow Health, Afya, Sea, Paysafe Group Holdings, Solar Inc, Aramark Holdings Corp, Lending, Holding, BioXcel Therapeutics, IHS Inc, Rewalk Robotics, Acurx Pharmaceuticals, Energizer Holdings, Power Solutions, Rekor Systems, Wine Estates, Momentus Inc, SIGMA Lithium Corporation, AlTi, QuickLogic Corporation, Arcturus Therapeutics, Dada Nexus, Solutions, Target Corp, Parts, ZIM Integrated Shipping Services, Alto Networks, Cisco Systems, Chemical & Mining Co, PennantPark Investment Corp, Copa Holdings S.A, Walmart, Arcos Dorados Holdings, ARCO, NICE, Body, Warner Music Group Corp, Ross Stores, Homes, Dolby Laboratories Inc, American Software, ESCO Technologies, ZTO, International, BJ's Wholesale, Jim Cramer's Charitable, CNBC, Maxx Locations: Macau, Chile, Cayman, Pasadena , California

☆ Amazon adds a new reason to get and keep Prime: member discounts on health-care services
▼ + stars: | 2023-11-08 | by ( Paulina Likos | ) www.cnbc.com time to read: +4 min

Amazon (AMZN) said on Wednesday that it's offering Prime members a discount on its new health-care service — another perk that should help bring more people into the online retailer's ecosystem. It provides members unlimited 24/7 access to virtual care as well as in-person, and remote primary care services. Prime members can add up to five people from their family to the One Medical plan for an additional $6 a month. Amazon offering a discounted subscription to One Medical's services is part of the company's efforts to expand the broader Prime flywheel by leveraging its 167 million Prime members. The goal of the Amazon Prime membership is to provide people with "one simple membership, something that provides shopping, savings, streaming and now positive health outcomes, said Jamil Ghani, SVP of Amazon Prime in a CNBC interview Wednesday.

Persons: Jeff Marks, It's, Tom Forte, Forte, Andy Jassy, Davidson, there's, Jamil Ghani, Jim Cramer's, Jim Cramer, Jim, John Love, Jason Redmond Organizations: Amazon, D.A, Amazon Web Services, Amazon Pharmacy, Amazon Prime, CNBC, Robotics Research, AFP, Getty Locations: Davidson, Sumner , Washington

☆ IQVIA cuts annual profit forecast on slow demand for medtech, analytics services
▼ + stars: | 2023-11-01 | by ( ) www.reuters.com time to read: +2 min

Nov 1 (Reuters) - IQVIA Holdings (IQV.N) cut its full-year profit forecast on Wednesday, citing weakness in demand for its analytics and medical technology solutions along with the impact of a stronger U.S. dollar. Thermo Fisher signaled that the demand slump from biotech clients for its contract research services could extend into the next year due to rising interest rates and a persistent funding crunch. On an adjusted basis, IQVIA reported a profit of $2.49 per share for the third quarter, topping estimates of $2.44 per share. The company now expects full-year adjusted profit to be between $10.16 and $10.23 per share, compared with its prior per-share forecast of $10.26 to $10.56. IQVIA now expects 2023 revenue between $14.89 billion and $14.92 billion, compared with its previous forecast of $15.05 billion to $15.18 billion.

Persons: IQVIA, Fisher, Christy Santhosh, Shweta Agarwal Organizations: IQVIA Holdings, Danaher Corp, Thomson Locations: Durham , North Carolina, Bengaluru

☆ This maker of an atrial fibrillation device has nearly 70% upside, JMP Securities says
▼ + stars: | 2023-10-23 | by ( Pia Singh | ) www.cnbc.com time to read: +2 min

Investors should scoop up shares of medical device provider AtriCure , according to JMP Securities, which expects the company to be a winner in one burgeoning medical device market. AtriCure develops, manufactures and sells devices that are used for the treatment of atrial fibrillation, or Afib; left atrial appendage management, or LAAM; and post-operative pain. The company's stock price has declined just about 19% so far this year, with almost all of that occurring this quarter. ATRC YTD mountain AtriCure stock. AtriCure's pain management division "adds an attractive layer of growth that should outpace ATRC's legacy product portfolios," Stauder said.

Persons: Daniel Stauder, Stauder, bode, AtriCure, — CNBC's Michael Bloom Organizations: JMP Securities

The logo of Johnson & Johnson is seen on a Brussels' office of the company in Diegem, Belgium September 21, 2023. Investors are focused on how J&J, now a standalone pharmaceutical and medical devices company, will reach its goal of $57 billion in drug sales by 2025. Johnson & Johnson recorded a $21-billion gain in the third quarter from the spin-off of its consumer health unit. Stelara, J&J's top-selling anti-inflammatory drug, brought in sales of $2.86 billion in the quarter, above LSEG estimates of $2.61 billion. Excluding its consumer health unit, J&J now expects 2023 adjusted profit of $10.07 to $10.13 per share, compared with its previous outlook of $10.00 to $10.10 per share.

Persons: Johnson, Yves Herman, MedTech, Cantor Fitzgerald, Louise Chen, Stelara, Joseph Wolk, Wolk, J, Bhanvi Satija, Sriparna Roy, Patrick Wingrove, Shounak Dasgupta Organizations: Johnson, REUTERS, Innovative Medicine, Reuters, Thomson, & $, & $ Locations: Brussels, Diegem, Belgium, Stelara, U.S, United States, Bengaluru, New York

☆ Johnson & Johnson beats on earnings and hikes outlook as medtech, pharmaceutical sales surge
▼ + stars: | 2023-10-17 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Johnson & Johnson on Tuesday reported adjusted earnings and revenue that topped Wall Street's expectations, and lifted its full-year guidance as sales in the company's pharmaceutical and medical devices businesses surged. Upon that split, J&J lowered its full-year sales and profit guidance. J&J also expects adjusted earnings per share of $10.07 to $10.13, up from a previous forecast of $10.00 to $10.10. The pharmaceutical giant reported net income of $4.31 billion, or $1.69 per share. That was flat compared with net income of $4.31 billion, or $1.62 per share, for the same period a year ago.

Persons: Johnson, J, Joseph Wolk Organizations: LSEG

☆ Many are betting Ozempic will reduce the need for knee surgery. What it means if they're wrong
▼ + stars: | 2023-10-14 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +5 min

Medical device stocks of all kinds were pummeled over the past week as investors tried to calculate the ripple effects of new weight loss drugs. While the use of the GLP-1 drugs to treat obesity is still very limited at this point, it is expected to soar to a $100 billion market or more, by some estimates. Judging by the momentum in the stocks, investors have been betting that as people lose weight, there will be a decline in knee replacement surgery. A case for more knee surgery? Based on Truist's polling of 50 hospital administrators, the analyst expects the third quarter will show a slowing pace of knee replacement surgeries compared to the first half of 2023.

Persons: We've, Bill Sutherland, Piper Sandler, Matt O'Brien, Stryker, Eli Lilly's Mounjaro, O'Brien, Richard Newitter, Newitter, Benchmark's Sutherland, Kaiser, Sutherland, — CNBC's Michael Bloom Organizations: American College of, Nordisk's Ozempic, Stryker, Surgery Partners, Permanente, Tenet Healthcare, Partners Locations: U.S, GLP

How GLP-1 drugs work Sorting through the facts reveals some likely winners and losers. LLY YTD mountain Eli Lilly shares year to date performance It is still early days for GLP-1 medications. Many have seen the rise of GLP-1 drugs as a threat to the medical device industry. Also, not all patients are able to tolerate GLP-1 drugs, which can cause side effects such as nausea. Among other medtech stocks, Plovanic sees GLP-1 drugs as an "incremental positive" for Dexcom, which makes continuous glucose monitors (CGMs), but an "incremental negative" for insulin pump makers like Insulet.

Persons: Insulet, Medtronic, Dexcom, BAX, NASH, Eli Lilly, Peter Verdult, Lilly, Eli Lilly aren't, Piper Sandler, Wegovy, Yasmeen Rahimi, Robbie Marcus, Marcus, hasn't, Baxter, David Low doesn't, William Plovanic, Craig Wong, Pan, Plovanic, Matt O'Brien, O'Brien, Rippling, Simeon Gutman, Morgan Stanley, Gutman, — CNBC's Michael Bloom Organizations: Novo Nordisk, Baxter International, Baxter, GLP, Citi, Novo, Bank of America, Viking Therapeutics, Pharmaceuticals, Pfizer, Amgen, Companies, Fisher, Reuters, Inspire, Systems, JPMorgan, RBC Capital, Walmart, underperformance Locations: GLP, U.S, DaVita, ResMed

☆ Stocks making the biggest moves premarket: Ford, Target, Walgreens, Domino's Pizza, First Solar and more
▼ + stars: | 2023-10-12 | by ( Brian Evans | ) www.cnbc.com time to read: +2 min

Target — The retailer rose 2.8% after Bank of America upgraded Target to buy from neutral. ResMed — The medtech device stock slipped 2% after a downgrade by RBC Capital Markets to sector perform from outperform. Plug Power — The battery stock added 1.2% after JPMorgan added the company to its positive catalyst watchlist, and highlighted potential near-term upside. First Solar — Stock in the solar panel maker added nearly 4% following an upgrade to overweight from Barclays, with analyst Christine Cho highlighting an attractive valuation. Domino's Pizza — Shares of the pizza delivery company slipped more than 3% on mixed third-quarter results.

Persons: ResMed, Christine Cho, Warby Parker, Janine Stichter, Jesse Pound, Michelle Fox, Pia Singh, Yun Li Organizations: Ford —, United Auto Workers, Target, Bank of America, Walgreens, Delta Air Lines, Delta, RBC Capital Markets, RBC, JPMorgan, Barclays, BTIG, BMO Capital Markets Locations: Kentucky, U.S

☆ This health care giant has 'unlocked potential' after a recent spinoff, RBC says
▼ + stars: | 2023-10-05 | by ( Pia Singh | ) www.cnbc.com time to read: +2 min

Johnson & Johnson is a buy after the company's consumer business spinoff earlier this year, according to RBC Capital Markets. The firm initiated Johnson & Johnson with an outperform rating and $178 price target, which suggests shares can climb about 14.5% from Wednesday's close. This separation has "unlocked potential" for Johnson & Johnson going forward, analyst Shagun Singh said. Singh also said the company's pharma franchise is poised to deliver competitive growth and that its medtech division is on pace to achieve "top-tier growth and profitability." The analyst added that Johnson & Johnson is trading below its historical multiples despite its improved financial profile since its Kenvue spinoff and that the company has potential upside from further M & A activity.

Persons: Johnson, Shagun Singh, Singh, —, — CNBC's Michael Bloom Organizations: RBC Capital Markets, Johnson, Pharma, company's pharma Locations: Wednesday's

☆ Here are Thursday's biggest analyst calls: Nvidia, Meta, Ford, Wingstop, American Express and more
▼ + stars: | 2023-10-05 | by ( Michael Bloom | ) www.cnbc.com time to read: +6 min

Bank of America initiates Wingstop as buy Bank of America said shares of the wing restaurant company are attractive. " Bank of America downgrades Carrier to underperform from neutral Bank of America said it sees residential headwinds. "We are initiating on the Alternative Asset Management sector with a Market Overweight rating. Deutsche Bank initiates AIG as buy Deutsche Bank initiated the insurance company with a buy and says shares are de-risked. Bank of America reiterates American Express as a top pick Bank of America said the credit card company is its favorite idea in the sector. "

Persons: Stifel, Wedbush, Morgan Stanley, Ford, CARR, Parker, ITW, Raymond James downgrades Clorox, Raymond James, CLX, Johnson, Wolfe, Bernstein, Chubb Organizations: BMO, Sinclair, Oculis, Citizens, CIT Group, Bank, JPMorgan, Barclays, Meta, Bank of America, Ford, General Motors, GM, UAW, of America, Nvidia, ISI, RBC, Johnson, Pharma, KKR, Alternative, Management, Asset Management, CART, Deutsche Bank, AIG, Citi, O'Reilly Automotive, O'Reilly, American Express Locations: CY24, U.S

An artificial heart by French manufacturer Carmat is seen during an interview with Reuters in Velizy, near Paris, January 11, 2021. Sources said Carmat, which had 24 million euros cash at mid-year, was looking to raise a total of around 100 million. Airbus said this week it had invested 50 million euros in Carmat but did not address whether it would spend more. It most recently invested 10 million euros in March 2022. Matra Defense paid a dividend of 207 million euros to Airbus in 2022, filings show.

Persons: Christian Hartmann, Jean, Luc Lagardere, Alain Carpentier, Carpentier, Stephane Piat, Emmanuel Macron, Thomas Toepfer, Piat, Samir Devani, Carmat, Tim Hepher, Michal Aleksandrowicz, Laura Lenkiewicz, Stephanie Hamel, Josephine Mason, Elaine Hardcastle Organizations: Reuters, REUTERS, Rights, Airbus, PARIS, Lagardere's Matra Defense, Carmat, Rx Securities, FDA, Zurich University, Matra Defense, Thomson Locations: Velizy, Paris, French, Carmat, United States, Lagardere, Taiwan

Johnson & Johnson is signing off on a new logo. Johnson & Johnson itself narrowed its focus to pharmaceuticals and medical devices. The signature logo was “one of the longest-used company emblems in the world,” J&J declared in a 2017 website post. “Everyone washed their baby with Johnson & Johnson baby shampoo,” she said. New Brunswick, New Jersey-based J&J also will rename its Janssen pharmaceutical segment, changing it to Johnson & Johnson Innovative Medicine.

Persons: Johnson, James Wood, ”, Vanessa Broadhurst, ” J, J, Laura Ries, Ries, wasn't Organizations: Janssen, Johnson Innovative Medicine, Associated Press Health, Science Department, Howard Hughes Medical Institute’s Science, Educational Media Group, AP Locations: New Brunswick , New Jersey

☆ Stocks making the biggest moves premarket: Enbridge, Roku, GitLab and more
▼ + stars: | 2023-09-06 | by ( Pia Singh | ) www.cnbc.com time to read: +4 min

Roku also lifted its third-quarter revenue guidance, saying it now expects revenue to range between $835 million and $875 million, versus prior guidance of $815 million. Along with the workforce reductions, Roku said it plans to consolidate office space and review its content slate to trim expenses. Zscaler posted adjusted earnings of 64 cents per share while analysts polled by LSEG, formerly known as Refinitiv, expected 49 cents. Additionally, the cybersecurity company said earnings and revenue should come in ahead of what analysts anticipate in the current quarter. GitLab — Shares of the technology platform jumped 6.5% in premarket trading following a strong second-quarter report postmarket Tuesday.

Persons: Roku, Zscaler, Needham, GitLab, LSEG, Asana, AeroVironment, Sam Subin, Michelle Fox Theobald, Jesse Pound Organizations: LSEG, Revenue, Dominion Energy, Dominion, UBS, Southwest Airlines —, Southwest, Novo Nordisk — Locations: Hastings, Hudson , New York, Enbridge, Dallas, Danish, Europe

☆ Here are Tuesday's biggest analyst calls: Nvidia, Apple, Disney, Walmart, Lowe's, Alphabet and more
▼ + stars: | 2023-09-05 | by ( Michael Bloom | ) www.cnbc.com time to read: +7 min

TD Cowen upgrades Domino's to outperform from market perform TD said in its upgrade of the stock that it sees upside to same-store sales. Bernstein reiterates Apple as market perform Bernstein said similarities exist between IBM 10 years ago and Apple today. Morgan Stanley reiterates Walmart as overweight Morgan Stanley sees an attractive risk/reward for Walmart shares. RBC upgrades American Express to outperform from sector perform RBC said the credit card company is "best positioned" to outperform. Jefferies reiterates Alphabet as buy The firm is more bullish on Alphabet shares after the company's recent Google Cloud event.

Persons: TD Cowen, Woodward, Uber, Cantor Fitzgerald, Wells, Bernstein, Morgan Stanley, Goldman Sachs, Lamb Weston, Stryker, Baird, Wolfe, Stifel, Jefferies, GOOGL's, We've Organizations: DIS, Media, Apple, IBM, Walmart, Bank of America, of America, Citi, Technologies, UBS, RBC, Dine Brands, Susquehanna, Barclays, Oracle, Vail Resorts, MTN, Google, Nvidia Locations: U.S, North America

☆ As weight loss drug stocks rallied on a landmark study, these stocks were over sold, analysts say
▼ + stars: | 2023-08-11 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +8 min

However, the pharmaceutical companies are making the case that weight loss can improve health, and possibly lower health-care costs over time. But analysts have said the news isn't all bad for such stocks, and many were fell too low on Tuesday. Deutsche Bank analyst Imron Zafar estimated Thursday that bariatric surgery accounts for about 5% of Intuitive Surgical's U.S. robotic surgery business, but has been driving much of the company's growth. Some of the surgeons Zafar spoke with said any drop off in bariatric surgery was likely to be offset by increased use of the robot for other procedures. But they expect the drugs will remain necessary because GLP-1 drugs have yet to show they improve fibrosis, which is associated with NASH.

Persons: nonalcoholic steatohepatitis, NASH, Abbott, Robbie Marcus, Marcus, Marcus doesn't, Goldman Sachs, Goldman, Stryker, Smith, Zimmer Biomet, Bariatric, Imron Zafar, Zafar Organizations: Novo Nordisk, Abbott Laboratories, CNBC, JPMorgan, Companies, Inspire Medical Systems, Resmed, Philips, Nephew, Deutsche Bank, Madrigal Pharmaceuticals, Sagimet Biosciences, Akero Therapeutics, Terns Pharmaceuticals, Viking Therapeutics, Madrigal Locations: U.S

☆ These are the most overweighted and underweighted stocks by socially conscious funds, according to Bernstein
▼ + stars: | 2023-08-02 | by ( Alex Harring | ) www.cnbc.com time to read: +2 min

A handful of the most well-known technology stocks are being somewhat ignored by socially conscious funds, according to Bernstein. Big technology names including Apple , Amazon , Meta , Microsoft and Alphabet were among the most underweighted stocks by North American funds that consider environmental, social and corporate governance factors when screening investment ideas. Big Tech has roared back to life this year, coming off 2022's selloff as investors bet on a better interest rate environment. Here are the 10 most underweighted stocks by North American funds: On the flip side, a wide swath of stocks accounted for the most held, relatively. Barclays analyst Craig Rye said the stock could actually benefit if hurricane season is worse than was previously expected.

Persons: Bernstein, Danaher, Craig Rye, Rye, —, Michael Bloom Organizations: Apple, Meta, Microsoft, North, Big Tech, Software, Nvidia, Insurance, Barclays, Fisher, Deere

☆ Johnson & Johnson to reduce its Kenvue stake by at least 80% through exchange offer
▼ + stars: | 2023-07-24 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Johnson & Johnson on Monday said it plans to reduce by at least 80% its stake in Kenvue, the consumer health business it spun out as an independent company earlier this year, via a stock exchange offer. J&J owns 89.6% of Kenvue's common stock, which amounts to more than 1.72 billion shares. The exchange offer, also known as a split-off, will allow J&J shareholders to swap all or a portion of their shares for Kenvue's common stock at a 7% discount. J&J first announced its intent to launch an exchange offer in its second-quarter earnings report on Thursday, but the company provided few details on the plan. When asked about J&J's planned exchange offer on Thursday, Kenvue CEO Thibaut Mongon told CNBC's "Squawk on the Street" that the company is "pleased with the way that the IPO has been received by shareholders."

Persons: Johnson, J, Joaquin Duato, Duato, Kenvue, J's, Thibaut Mongon, CNBC's Organizations: J Locations: Kenvue

☆ J&J's strong quarter was amplified by new details around its big Kenvue consumer unit stake
▼ + stars: | 2023-07-20 | by ( Zev Fima | ) www.cnbc.com time to read: +12 min

Johnson & Johnson (JNJ) reported strong second - quarter profit and revenue before the opening bell Thursday, with better-than-expected results both domestically and internationally, as well as across all major operating segments. It's possible that J & J management will offer up Kenvue shares at a discount to market value. Regardless, arbitrage isn't our game and we want to be invested in J & J for the long term. The only change — since J & J owns 89.6% of Kenvue — is that 10.4% of earnings generated since Kevnue went public in early May to the end of the quarter are no longer attributed to J & J. A Johnson & Johnson building is shown in Irvine, California.

Persons: Johnson, —, Kevnue, J, J's, prioritization, Jim Cramer's, Jim Cramer, Jim, Mike Blake Organizations: Dow, Pharmaceutical, Management, J's, Johnson, J, Consumer, Consumer Health, Pharmaceutical Pharmaceutical, CNBC, & $ Locations: Kenvue, JNJ, KVUE, Spravato, Irvine , California

☆ J&J CFO Joseph Wolk on Q2 earnings beat: We're in a very strong position for second half of 2023
▼ + stars: | 2023-07-20 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailJ&J CFO Joseph Wolk on Q2 earnings beat: We're in a very strong position for second half of 2023Johnson & Johnson CFO Joseph Wolk joins 'Squawk Box' to discuss the company's quarterly earnings results, which topped Wall Street’s expectations due to strong sales growth from the company’s medtech business, and more.

Persons: Joseph Wolk, Johnson

☆ Johnson & Johnson beats on earnings, hikes full-year guidance as medtech sales surge
▼ + stars: | 2023-07-20 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +1 min

Johnson & Johnson on Thursday reported second-quarter revenue and adjusted earnings that topped Wall Street's expectations, and lifted its full-year guidance as sales from the company's medtech business jumped. That compares with a net income of $4.8 billion, or $1.80 per share, for the same period a year ago. Excluding certain items, adjusted earnings per share were $2.80 for the period. J&J is now forecasting full-year sales of $98.80 billion to $99.80 billion, about $1 billion higher than the guidance provided in April. The company raised its 2023 adjusted earnings outlook to $10.70 to $10.80 per share, from a previous forecast of $10.60 to $10.70 per share.

Persons: Johnson Organizations: UnitedHealth, Elevance, Refinitiv

Search resuls for: "medtech"

25 mentions found